Kornimate/medical-research-clean huggingface dataset:
chidamide prevents recurrence of high-risk aml after allo-hsct

Conditions: Leukemia, Myeloid, Acute

Summary: the goal of this phase i/ii clinical trial is to test in high-risk acute myeloid leukemia (aml) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-hsct). the main question it aims to answer is: • the efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate and gvhd incidence in high-risk aml patients after allo-hsct. participants will take oral chidamide (epidaza) until 180 days after allo-hsct.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old and ≤ 65 years old when signing the informed consent form (icf); 2. kps score \> 60 or ecog score 0-2; 3. the expected survival period \> 3 months; 4. received allo-hsct and achieved complete remission (cr); 5. reach the standard of hematopoietic reconstitution (neutrophil count ≥ 0.5×10\^9/l for 3 consecutive days without g-csf application, platelet count ≥ 20×10\^9/l for 7 consecutive days without platelet transfusion, hb ≥ 80 g /l without red blood cell transfusion); and neutrophil count ≥ 1.5×10\^9/l, platelet count ≥ 50×10\^9/l within 45 days after transplantation; 6. no central nervous system involvement or clinical symptoms after transplantation; 7. those who have no serious functional damage to important organs of the body; 8. fully understand and be informed of this study and sign the icf; willing to follow and have the ability to complete all test procedures; 9. females of childbearing age must afford a serum pregnancy test within 7 days before the first dose, and the result should be negative; female participants and their partners should agree to use effective contraception from signing the icf until 6 months after the last dose. exclusion criteria: 1. serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.; 2. uncontrolled active infection (including bacterial, fungal, or viral infection), and drug treatment is ineffective; 3. participating in other clinical studies, or planning to start treatment in this study and less than 4 weeks before the end of treatment in the previous clinical study; 4. poor graft function (pgf) occurred after allo-hsct; 5. combined with other malignant tumors and require treatment; 6. active gvhd; 7. have a history of allergy to chidamide; 8. pregnant or lactating females; 9. patients with known history of human immunodeficiency virus (hiv) virus infection and/or acquired immunodeficiency syndrome; 10. patients with active chronic hepatitis b or active hepatitis c; 11. history of prolonged qt syndrome; 12. patients considered by other researchers to be unsuitable for this study.
physical capacity in hodgkin lymphoma survivors

Conditions: Hodgkin Lymphoma, Adult; Cardiovascular Diseases; Radiation Effect; Chemotherapy Effect

Summary: the study aims to investigate if physical capacity obtained in the cardiopulmonary exercise test can predict cardiovascular alterations in hodgkin lymphoma (hl) survivors. in addition, to study the effects of exercise training on physical capacity and cardiovascular responses in these patients.

hodgkin lymphoma (hl) is a hematological neoplasia that mainly affects young people. anthracycline-based chemotherapy, followed or not by mediastinal radiotherapy, substantially improves prognosis in this set of patients. observational studies have shown that cardiovascular disease is the most non oncologic cause of death in this population. coronary artery disease (cad) affects 26% of survivors after 10 years of absence of hl . however, the early intervention and the assessment to predict the cardiovascular risk remain little known. in this study, the investigators will test the hypothesis that physical capacity can predict the cardiovascular alterations in hl survivors. in addition, exercise training improves physical capacity and heart rate responses in this set of patients.

Eligibility criteria:
inclusion criteria: * hodgkin lymphoma survivors * over 18 years old * chemotherapy with anthracycline and mediastinal radiotherapy in the last 5 years or more exclusion criteria: * renal insufficiency * pregnant women, * iodinated contrast allergy, * life expectancy less than 1 year.

Keywords: oxygen consumption physical training heart hate cardioprotection
evaluation of periomonitor for detection of oral inflammatory load (oil) in human subjects.

Conditions: Oral Inflammation

Summary: the purpose of this multicenter, prospective, single arm study is to evaluate the efficacy and safety of periomonitor as an aid to the detection of oral inflammation associated with periodontal diseases. periomonitor is an ivd device for the rapid, semi-quantitative detection of neutrophil enzyme activity in oral samples. this test is intended for prescription use at point-of-care ("poc") settings by health care professionals.

the purpose of this multicenter, prospective, single arm study is to evaluate the efficacy and safety of periomonitor as an aid to the detection of oral inflammation associated with periodontal diseases. periomonitor is an ivd device for the rapid, semi-quantitative detection of neutrophil enzyme activity in oral samples. this test is intended for prescription use at point-of-care ("poc") settings by health care professionals. the primary objective of this study is to evaluate the positive percent agreement (ppa)ppa and the negative percent agreement (npa)npa of periomonitor for semi-quantitative detection of neutrophil enzyme activity in human oral specimens, to detect oral inflammation associated with periodontal diseases (subjects having more than 50 000 neutrophils/ml in their oral specimen or having more than 10% of bleeding sites when tested with the bop method). the secondary objective is to validate the claim that periomonitor can be used in poc settings (i.e., representative of the intended users and under conditions similar to the conditions of use), at the time of the consultation, with instant availability of results, by healthcare professionals (hcp) working in a dental clinic (i.e. with the background, education, and training of those who will perform the test in its intended environment) that are not qualified laboratory technicians, to make immediate and informed decisions about patient care.

Eligibility criteria:
inclusion criteria: * subject \> 18 years old; * subject fluent in english; and * subject has signed the icf exclusion criteria: * subject with altered mental status/inability to provide informed consent or follow the procedure of the study; and * subject using immunosuppressants including biologics such as adalimumab (humira) and infliximab (remicade); or calcineurin inhibitors such as tacrolimus (envarsus xr or protopic) and cyclosporine (gengraf, neotal or sandimmmune); or corticosteroids (prednisone); or azathioprine (imuran) * oral rinse specimens received 5 days or more after periomonitor testing by the clinical laboratory * previous enrolment into the current study.
efficacy and safety of tongbi capsule in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: this study evaluates the efficacy and safety of tongbi capsule compared with placebo in the treatment of knee osteoarthritis in adults.half of participants will receive tongbi capsule in combination,while the other half will receive a placebo.


Eligibility criteria:
inclusion criteria: 1.45-75 years of age (including 45 years and 75 years old), men and women are not limited. 2. western medicine diagnosis of knee osteoarthritis, clinical classification for primary. 3.the severity of the imaging classification of k-l≤ⅲ; 4. treatment vas pain scores than 40mm (select the subjects most obvious limb pain symptoms). 5. informed consent form signed by the patient or legal representative. exclusion criteria: 1. within 3 months prior to the trial, the patients were treated within intra-articular treatment. 2. 4 weeks before the treatment, corticosteroids, non steroidal drugs, intra-articular injections or other drugs to improve the condition (such as cartilage protective agents) were used. 3. the screening period has any disease history or evidence: the basic of serious cardiovascular and cerebrovascular diseases; an active, recurrent peptic ulcer or other hemorrhagic disease risk; sales and other serious diseases of digestive system; an associated with malignant tumors, blood, or other serious diseases or system; patients who are unable to cooperate or cooperate with other mental disorders. 4. before the screening, any laboratory test indicators meet the following standards: an admission of liver and kidney function showed that alt and ast is more than 1.5 times the upper limit of the normal value, cr is more than 1.2 times the upper limit of normal (reference research center laboratory where the range of normal value); an other clinically significant laboratory abnormalities, and the researchers judged not into the group. 5. allergic constitution or allergic to tongbi capsul, excipients or similar ingredients; 6. professional athletes; 7. doubt or indeed history of alcohol and drug abuse; 8. participants who participated in other clinical trials within the first 3 months; 9. the researchers believe that patients should not participate in this clinical trial.
multimodality cardiovascular imaging for the translation of therapies for vascular activation after mi

Conditions: Myocardial Infarction

Summary: subjects with urgently reperfused type i myocardial infarction (mi) will be recruited and randomized to receive either placebo or the oral inflammasome (nlrp3) inhibitor dapansutrile. the primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be plaque inflammatory activity and coronary microvascular function.


Eligibility criteria:
inclusion criteria: * acute type i myocardial infarction (nstemi or stemi) * reperfusion therapy planned or performed within prior 48 hrs * carotid or femoral artery plaque at baseline, or carotid intima media thickness \>1.5 mm exclusion criteria: * type ii mi * failed primary pci or need for emergent bypass surgery * severe heart failure (nyha class iv) * life-threatening complication of mi (myocardial rupture, ischemic vsd, papillary muscle rupture) * refractory ventricular arrhythmias * allergy to dapansutril, olt177, or drugs in the same class * co-morbidity limiting 6 month survival * active malignancy or recent malignancy with any systemic anti-cancer treatment * active infection * use of immunosuppressive medications or immunodeficiency disorder * neutropenia (anc \<2,000) * moderate or severe renal impairment (gfr \<30 ml/min) * recent stroke (within previous 3 months) * allergy to ultrasound enhancing agents or polyethylene glycol * pregnancy or breastfeeding
an exploratory pharmacogenomic study of monotherapy erbitux in subjects with metastic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of this study is to predict response to erbitux as a single agent in patients with metastatic colon cancer


Eligibility criteria:
inclusion criteria: * measurable disease tumor available for biopsies. life expectancy of at least 3 months. exclusion criteria: * known or documented brain metastases prior to cetuximab therapy.
efficacy of wrist acupressure band on sleep quality in medical trainees

Conditions: Sleep; SLEEP DISTURBANCES Nec in ICD9CM; Anxiety

Summary: background: medical trainees frequently experience sleep disturbances, with shift work being a major contributing factor impacting their performance and overall wellbeing. traditional treatments for sleep disorders often involve medications and hypnotics with potential side effects, highlighting the need for alternative strategies. acupressure, particularly at the p6 (neiguan) point, has shown promise in improving sleep and reducing anxiety. objective: this study aimed to evaluate the efficacy of wristband acupressure applied to the p6 point in improving sleep quality, anxiety levels, and overall well-being among medical trainees. methods: a single-blinded, cross-over randomized controlled trial was conducted at the american university of beirut medical center (aubmc), involving 10 medical trainees. participants were randomized in blocks to either the intervention group, receiving wristband acupressure at the p6 point, or the control group, receiving acupressure at a sham point. standardized, validated questionnaires were used to assess sleep quality (psqi), anxiety (gad-7), and well-being (who-5) before and after each intervention period. ethical approval was obtained from the institutional review board, and participant confidentiality was maintained


Eligibility criteria:
inclusion criteria: residents, fellows and med-4 students at aub. exclusion criteria: * being enrolled in another sleep study * currently on sleep medications: benzodiazepines, antihistamines, muscle relaxants, magnesium supplements, herbal supplements that help with sleep including chamomile, ashwaghanda and melatonin * daily alcohol consumers
protection from cisplatin ototoxicity by lactated ringers

Conditions: Hearing Loss

Summary: the purpose of this study is to determine if lactated ringer's solution is effective in patients undergoing chemotherapy with cisplatin for head and neck cancer in regards to cisplatin-induced hearing loss.

about one-third of people who have been given cisplatin, as part of their chemotherapy treatment, develop hearing loss. the purpose of this study is to determine if some degree of hearing loss can be prevented by use of lactated ringer's solution in the middle ear. to study this, patients will use drops in their ears; lactated ringer's will be placed in one ear and an inactive saline solution will be placed in the other. ofloxacin, an eardrop antibiotic will be placed in each ear at the same time. each participant will receive a hearing evaluation before each dose of cisplatin and another evaluation 2 to 4 weeks after the final treatment.

Eligibility criteria:
inclusion criteria: * patients with cancer to be treated with cisplatin. * patients expected to receive a minimum of 3 rounds of chemotherapy. * patients receiving a minimum dose of cisplatin of 70 mg/m2 exclusion criteria: * patients who have had middle ear surgery. * patients who have active external or middle ear disease * patients who have preceding pure tone average of \>40 db hl

Keywords: cisplatin ototoxicity lactated ringer's ear cancer hearing loss hearing loss due to cisplatin ototoxicity
health-related qof between oab-wet and oab-dry women

Conditions: Quality of Life

Summary: overactive bladder syndrome (oab) has a great negative impact on health-related quality of life. in literatures, few studies reported the comparisons of health related quality of life between oab-wet and oab-dry female patients. thus, our aim is to compare the clinical variables and health-related quality of life between oab-wet and oab-dry women.

between july 2009 and january 2018, all women with oab visiting a medical center for evaluation were reviewed. the classification of oab-wet or oab-dry is based on the record of the three-day bladder diary of each patient. the diagnosis of oab in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. the presence of at least one episode of urgency associated incontinence was defined to be oab-wet, otherwise, oab-dry. besides, only female oab patients with available king's health questionnaire (khq) data were reviewed in this study.

Eligibility criteria:
inclusion criteria: 1. more than 20-year-old 2. female 3. diagnosed with overactive bladder by bladder diary exclusion criteria: 1. younger than 20-year-old 2. pregnant or planned to be pregnant

Keywords: health related quality of life overactive bladder bladder diary
comparison of boric acid vs. terconazole in treatment of rvvc

Conditions: Vulvovaginal Candidiasis

Summary: vulvovaginal candidiasis (vvc) caused by candida species, predominantly c. albicans is considered one of the most common infections of the lower female genital tract affecting 75% of women at least once in their lifetime. recurrent vvc (rvvc) is arbitrarily defined as four or more episodes every year. rvvc is a debilitating, long-term condition that can severely affect the quality of life of women. several factors have been associated with rvvc such as prolonged use of antibiotics, inadequately treated infection, uncontrolled diabetes, immune mechanisms (e.g. hiv), oral contraceptive use as well as the resistance of non-albicans candida species (e.g. c glabrata, c krusei) to conventional antifungal agents as azoles. fluconazole administered orally is the most commonly used antifungal drug in the case of rvvc. however, in the last decade, fluconazole-resistant c albicans has been reported in women with rvvc. terconazole is a broad-spectrum, triazole antifungal treatment agent for both c albicans and non-albicans. its use (80 mg vaginal suppository daily for 6 days) was as effective as two doses of oral fluconazole (150 mg) in the treatment of patients with severe vvc and rvvc. boric acid or boracic \[b(oh)3\] is a weak acid with proven antifungal action. in rvvc especially in azole-resistant strains and in non-candida albicans, 600 mg of the boric acid vaginal suppository is recommended once daily for 2 weeks. this regimen has a mycologic cure rate varied from 40% to 100%. however, there are no published studies comparing the intravaginal use of boric acid with terconazole for rvvc. accordingly, a prospective randomized study in patients with rvvc will be conducted to address this important issue.


Eligibility criteria:
inclusion criteria: * diagnosis of rvvc will be defined as four or more episodes of vvc that occurred during the previous 12-month period. * has symptoms and signs of vvc e.g. itching, burning, discharge, and erythema. * documented vvc on high vaginal swabs (hvss) by the demonstration of blastospores and pseudohyphae in a wet vaginal smear treated with 10% potassium hydroxide, and a positive fungal culture. * age: 18-50 years old and premenopausal. * agree to abstain from sexual intercourse during the treatment period. * agree to abstain from using any other vaginal product during the study period. exclusion criteria: * postmenopausal. * pregnancy. * sexually transmitted infection (chlamydia, gonorrhea, trichomonas). * any antifungal or antibiotic use 14 days prior to treatment. * gynecological conditions requiring treatment e.g. bartholin's cyst, abscess, pid. * patients receiving corticosteroids or immunosuppressive therapy. * patients expected to menstruate within seven days of the start of treatment.
choice: carotid stenting for high surgical-risk patients

Conditions: Carotid Artery Disease

Summary: the purposes of this study is to 1) provide additional information that the commercially available abbott vascular carotid stent systems and embolic protection systems can be used successfully by a wide range of physicians under commercial use conditions. 2) provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the centers for medicare and medicaid services (cms) coverage to a broader group of patients.

the choice study will provide a mechanism for collection of data from abbott vascular's carotid stent systems and embolic protection systems when used by a broad group of physicians under commercial use conditions. the original capture and exact studies had built-in features that limited the ability to collect on-going real world data because they restricted the number of sites that could participate (up to 150 sites) and limited enrollment at each site (up to 50 patients per site). this study will not have these restrictions. the choice study will also provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the centers for medicare and medicaid services (cms) coverage to a broader group of patients.

Eligibility criteria:
inclusion criteria: 1. patient or patient's legally authorized representative provided informed consent. 2. patient is considered at high risk for carotid endarterectomy (cea). 3. patient requires percutaneous carotid angioplasty and stenting for carotid artery disease. 4. patients physician intends to use an rx acculink with either the rx accunet or emboshield nav 6 in the carotid artery or the patients physician intends to use an xact with the emboshield or emboshield nav6 in the carotid artery as per the fda approved indications for use as outlined. exclusion criteria: there are no exclusion criteria for this study
a study to determine the preferred dose of the drug, lisinopril, for preventing urinary toxicity following radiotherapy for prostate cancer

Conditions: Prostate Cancer; Radiation Toxicity; Urinary Complication

Summary: this study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. this study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.


Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of adenocarcinoma of the prostate and are candidates for curative-intent external beam radiation (with or without androgen deprivation therapy, adt) at the wilmot cancer institute department of radiation oncology. radiotherapy may be either primary, adjuvant or salvage. it may be part of combined treatment with androgen deprivation therapy. * be stage m0 based on the standard of care staging imaging * be able to read english * have the psychological ability and general health that permits completion of the study requirements and required follow up * be ≥18 and \< 70 years of age * have ecog performance status of 0 to 2 within 180 days prior to enrollment * have adequate renal function with creatinine clearance \> 30 ml/min within 30 days prior to registration * have hematologic and hepatic function deemed adequate for planned treatment by the treating investigator within 90 days prior to registration, including: * hemoglobin ≥9.0 g/dl, independent of transfusion and/or growth factors * platelet count ≥100,000/µl independent of transfusion and/or growth factors * have a baseline systolic blood pressure of \>130. exclusion criteria: * have received prior pelvic radiotherapy * be taking lisinopril or other ras modifying drug within two months prior to registration * have had a prior allergic reaction to lisinopril